background: disability is the most important determinants of disease course, treatment and rehabilitation outcomes and consequently the quality of life in patients with multiple sclerosis. the aim of the present study was to determine the relationship of disability and quality of life in multiple sclerosis patients.   methods: this cross-sectional study was performed on 325 patients referred to...

Objective: To evaluate the clinical course of MS in individuals with onset of MS before age 16. Methods: Patients with onset of MS before age 16 (n 116) with complete clinical information on the clinical course from the MS Clinic at The University of British Columbia (UBC) Site Hospital computerized database (MS-COSTAR) were included in this study. The data were compared to those from the Canad...

how to cite this article: najafi mr, najafi ma, nasr z. diagnosis and management of multiple sclerosis in children. iran j child neurol. summer 2016; 10(3): 13-23. abstract growing evidence indicates the safety and well toleration of treatment by disease-modifying in children suffering multiple sclerosis (ms). the treatment is not straight forward in a great number of patients, thus patients wi...

a prior history of healthy lifestyle may be misleading when we consider associated risk factors for developing a serious and debilitating condition such as multiple sclerosis under extreme stress. the author reports a case of a woman who lived a healthy life and yet experienced an unexpected event leading to the diagnosis of multiple sclerosis. the patient’s condition was predominantly provoked...

BACKGROUND Although multiple sclerosis is considered as an inflammatory demyelinating disease of young adults, nearly 3% of patients manifest it under the age of 16 years. The aim of this study was to highlight the clinical and demographic features of early-onset multiple sclerosis in Isfahan, Iran. METHODS This prospective study concerned multiple sclerosis patients in whom the disease start...

background: intravenous immunoglobulin (ivig) is an established treatment of immune mediated demyelinating neuropathy including guillain-barré syndrome and chronic inflammatory demyelinating polyneuropathy. recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. ivig exerts a number of effects, which may be beneficial in treating multiple sclerosis (ms): reductio...